{"filing":{"accession_number":"0001213900-26-112109","cik":"0001851484","ticker":"CTOR","company_name":"CITIUS ONCOLOGY, INC.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-19","primary_document":"ea0309307-8k_citius.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026112109/ea0309307-8k_citius.htm"},"events":[{"id":37605,"run_id":34655,"accession_number":"0001213900-26-112109","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Citius Oncology received formal notice from Nasdaq granting an extension through April 19, 2027 to comply with the $1.00 per share bid price requirement under Nasdaq Listing Rule 5550(a)(2). The disclosure explicitly states that if the company fails to regain compliance by that date, Nasdaq will provide written notice that the stock is subject to delisting. This is a classic delisting-risk disclosure under Item 8.01, with a specific compliance deadline and clear consequences for non-compliance.","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42371,"accession_number":"0001213900-26-112109","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Citius Oncology received formal notice from Nasdaq granting an extension through April 19, 2027 to comply with the $1.00 per share bid price requirement under Nasdaq Listing Rule 5550(a)(2). The disclosure explicitly states that if the company fails to regain compliance by that date, Nasdaq will provide written notice that the stock is subject to delisting. This is a classic delisting-risk disclosure under Item 8.01, with a specific compliance deadline and clear consequences for non-compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:12:23.219336+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42371,"accession_number":"0001213900-26-112109","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Citius Oncology received formal notice from Nasdaq granting an extension through April 19, 2027 to comply with the $1.00 per share bid price requirement under Nasdaq Listing Rule 5550(a)(2). The disclosure explicitly states that if the company fails to regain compliance by that date, Nasdaq will provide written notice that the stock is subject to delisting. This is a classic delisting-risk disclosure under Item 8.01, with a specific compliance deadline and clear consequences for non-compliance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:12:23.219336+00:00","company_name":"CITIUS ONCOLOGY, INC.","ticker":"CTOR","filing_date":"2026-10-23"}]}